Filtered By:
Condition: Thrombosis
Cancer: Endometrial Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 67 results found since Jan 2013.

Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study
Conclusions:The risks of cardiovascular disease and cancer were not elevated among postmenopausal women using vaginal estrogens, providing reassurance about the safety of treatment. Objective: To determine the association between use of vaginal estrogen and risk of a global index event (GIE), defined as time to first occurrence of coronary heart disease (CHD), invasive breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, or death from any cause. Methods: For this prospective observational cohort study, we used data from participants of the Women's Health Initiative Observat...
Source: Menopause - December 22, 2017 Category: OBGYN Tags: Original Articles Source Type: research

HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
Abstract ABSTRACT Hormone replacement therapy (HRT) remains the gold standard for treatment of climacteric symptoms in menopausal women; it is relatively safe in healthy subjects for at least 5 years, provided it had been initiated before the age of 60 years and/or within 10 years from menopause. Estrogen probably adds some cardioprotection, that can, however, be obscured by progestogens, especially medroxyprogesterone acetate (MPA). Oral HRT is associated with an increased risk of venous thromboembolism (VTE), gallbladder disease and possibly stroke. The increased occurrence of all these events can be prevented b...
Source: Climacteric - July 19, 2013 Category: Geriatrics Authors: L'hermite M Tags: Climacteric Source Type: research

Managing menopause.
Authors: Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W, Menopause and Osteoporosis Working Group, Fortier M, Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Graves L, Guthrie B, Khan A, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W Abstract OBJECTIVE: To provide updated guidelines for health care providers on the management of menopause in asymptomatic healthy women as well as in women presenting with vasomotor or urogenital symptoms and on considerations related to cardiovascular disease, breast cancer, urogynaecology, and sexuality. OUTCOMES: Lifestyle...
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - December 2, 2014 Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research

For post-menopausal women, vaginal estrogens do not raise risk of cancer, other diseases
This study, the first to examine potential adverse health effects in users of vaginal estrogen compared with non-users, suggests that vaginal estrogen therapy is a safe treatment for genitourinary symptoms such as burning, discomfort, and pain during intercourse associated with menopause.AUTHORSThe paper ’s authors are Dr. Carolyn Crandall of UCLA; Kathleen Hovey of the State University of New York at Buffalo; Christopher Andrews of the University of Michigan; Dr. Rowan Chlebowski of City of Hope; Marcia Stefanick of Stanford University; Dr. Dorothy Lane of the State University of New York at Ston y Brook; Dr. Jan Shifre...
Source: UCLA Newsroom: Health Sciences - August 16, 2017 Category: Universities & Medical Training Source Type: news

P-013 Use of the Solitaire Device for Emergency Revascularization of the Superior Mesenteric Artery
ConclusionsThe techniques and equipment used for acute stroke intervention may be suitable for acute recanalization of peripheral vessels, under the right circumstances. As with many surgical interventions, a multidisciplinary approach may at times yield a novel and effective strategy for a difficult clinical problem.DisclosuresJ. Dalfino: None. A. Paul: None. J. Hnath: None.
Source: Journal of NeuroInterventional Surgery - July 28, 2016 Category: Neurosurgery Authors: Dalfino, J., Paul, A., Hnath, J. Tags: Oral poster abstracts Source Type: research

Long-term hormone therapy for perimenopausal and postmenopausal women.
CONCLUSIONS: Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT, provided they do not have specific contraindications. HT may be unsuitable for some women, including those at increased risk of cardiovascular disease, increased risk of thromboembolic disease (such as those with obesity or a history of venous thrombosis) or increased risk of some types of cancer (such as breast cancer, in women with a uterus). The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well docu...
Source: Cochrane Database of Systematic Reviews - January 16, 2017 Category: Journals (General) Authors: Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J Tags: Cochrane Database Syst Rev Source Type: research

Drugs to be offered to women at high risk of breast cancer
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease. They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older. The updated guideline has also made changes to the recommende...
Source: NHS News Feed - June 25, 2013 Category: Consumer Health News Tags: Cancer Medical practice QA articles Source Type: news

HRT increases ovarian cancer risk by small amount
Conclusion This systematic review and meta-analysis showed that ovarian cancer risk was significantly increased in current HRT users, even in those with less than five years of HRT use (the average was three years). In ex-users, risks decreased the longer ago HRT use had stopped, but risks during the first few years after stopping remained significant. Furthermore, about a decade after stopping, long-duration hormone therapy use (average nine years of HRT use), there still seemed to be a small excess risk. The review has a few limitations, however. The main one is that the review was heavily influenced by just two of t...
Source: NHS News Feed - February 13, 2015 Category: Consumer Health News Tags: Cancer Medication Older people Source Type: news

Diagnosis of an aortic valvular lesion
From the question on page 719 Clinical introduction A 59-year-old woman with hypertension presented with right-sided weakness and vision loss. Her vital signs were normal; cardiopulmonary exam was significant for a systolic and diastolic murmur. MRI of the brain showed multiple chronic bilateral infarctions, and Doppler ultrasound revealed acute left lower extremity deep vein thrombosis. Transthoracic echocardiography (TTE) to determine cardioembolic source of stroke was significant only for severe aortic valve regurgitation. To assess for cardiac vegetations, transoesophageal echocardiography (TEE) was performed (figure 1...
Source: Heart - April 9, 2015 Category: Cardiology Authors: Elboudwarej, O., Wei, J., Siegel, R. Tags: Drugs: cardiovascular system, Echocardiography, Image challenges, Hypertension, Venous thromboembolism, Aortic valve disease, Clinical diagnostic tests Source Type: research

The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Authors: Parish SJ, Gillespie JA Abstract This review describes the evolving role of oral hormone therapy (HT) for treating menopausal symptoms and preventing osteoporosis, focusing on conjugated estrogens/bazedoxifene (CE/BZA). Estrogens alleviate hot flushes and prevent bone loss associated with menopause. In nonhysterectomized women, a progestin should be added to estrogens to reduce the risk of endometrial cancer. Use of HT declined since the Women's Health Initiative (WHI) studies showed that HT does not prevent coronary heart disease (CHD) and that conjugated estrogens/medroxyprogesterone acetate increased th...
Source: Postgraduate Medicine - February 1, 2017 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Abstract P2-01-23: Long-term follow-up of persistent breast dermopigmentation after sentinel lymph node identification using superparamagnetic iron oxide particles (SIENNA+(R))
Patients with breast cancer (BC) and those at high risk for BC are often reluctant to initiate Tamoxifen (Tam) due to potential adverse events (AEs) such as deep vein thrombosis (DVT), pulmonary embolus (PE), acute ischemic stroke (AIS), myocardial infarction (MI) and endometrial cancer (EC). Some decline this life saving therapy due to fear of AEs. AE rates from RCTs are low, but AE rates in the general population are not well documented.Methods: The MarketScanR database (2010-2013) was searched for patients aged 30-64 with a prescription of Tam active for more than 120 days. Patients with prior DVT, PE, AIS, MI or EC wer...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: K Hannebicque, L Boulanger, E Bogart, S Giard, MP Chauvet, JL Houpeau Tags: Poster Session Abstracts Source Type: research

Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study
Conclusions: Vaginal estrogen use was not associated with a higher risk of cardiovascular disease or cancer. Our findings lend support to the safety of vaginal estrogen use, a highly effective treatment for genitourinary syndrome of menopause.
Source: Menopause - June 1, 2019 Category: OBGYN Tags: Original Articles Source Type: research

Impact of Body Mass Index on Obesity-Related Cancer and Cardiovascular Disease Mortality; The Japan Collaborative Cohort Study
CONCLUSION: A BMI ≥ 25 kg/m2 is associated with an increased risk of obesity-related cancer in women and CVD in both sexes.PMID:34880165 | DOI:10.5551/jat.63143
Source: Journal of Atherosclerosis and Thrombosis - December 9, 2021 Category: Cardiology Authors: Masaaki Matsunaga Hiroshi Yatsuya Hiroyasu Iso Yuanying Li Kazumasa Yamagishi Naohito Tanabe Yasuhiko Wada Atsuhiko Ota Koji Tamakoshi Akiko Tamakoshi JACC Study Group Source Type: research